Compare IDEXX Laboratories, Inc. (IDXX) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Vanguard Total International Stock Index Fund ETF — how do they compare? IDEXX Laboratories, Inc. trades at $558.94 (market cap $44.95B), while Vanguard Total International Stock Index Fund ETF trades at $87.78. The key difference: Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | VXUS | |
|---|---|---|
Market Cap | $44.95B | — |
Sector | Health | Sector/Thematic |
52-Week High | $766.68 | $87.54 |
52-Week Low | $526.44 | $70.87 |
Enterprise Value | $45.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
VXUS, the Vanguard Total International Stock ETF, trades at $87.54, up 0.82% today. The technical outlook is bullish based on moving averages, though oscillators are neutral and RSI levels suggest potential overbought conditions. Recent news highlights strong institutional buying and a 27.82% total return over the past year, emphasizing its role in diversifying beyond U.S. equities at a valuation discount.
The outlook for VXUS is positive, driven by international diversification benefits and strong recent performance. Key risks include global economic sensitivity and potential inflation impacts. Analyst sentiment is generally favorable, with institutional accumulation supporting long-term growth potential for investors seeking broad non-U.S. market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
